Peptides vs TRT: testosterone replacement therapy (TRT) replaces testosterone directly and is backed by large randomized trials, including TRAVERSE in 5,246 men, which found no increase in heart attacks, strokes or cardiovascular deaths versus placebo.[3] “Peptide therapy vs testosterone therapy” usually means one of two things: signals such as hCG, gonadorelin or kisspeptin-10 that prompt the testes to make more of your own testosterone,[6][10] or growth hormone peptides, which raise IGF-1, not testosterone.[13] Only TRT and hCG are FDA-approved for low testosterone in men, and hCG only for low testosterone caused by a pituitary or brain problem.[4][6]
See the hCG, gonadorelin and kisspeptin-10 profiles, or the muscle and metabolism peptides hub.
Peptides vs TRT at a glance
| TRT (testosterone) | Axis peptides (hCG, gonadorelin, kisspeptin-10) | Growth hormone peptides | |
|---|---|---|---|
| How it works | Replaces testosterone[1] | Signals the testes to make testosterone[6][10] | Raises growth hormone and IGF-1[13] |
| Raises testosterone | Yes[2] | Yes, if testes respond[7][11] | No |
| Effect on fertility | Suppresses sperm production[1] | hCG can maintain testicular testosterone on TRT[7] | Not studied |
| Largest trial | TRAVERSE, 5,246 men[3] | Small studies[7][10] | Retrospective chart review of 14 men[13] |
| FDA status | Approved; labels updated 2025 and 2026[4][5] | hCG approved;[6] gonadorelin discontinued;[9] kisspeptin-10 not approved[12] | Only tesamorelin approved, for HIV belly fat |
| Controlled substance | Schedule III[15] | No | No |
How each works
Your brain releases GnRH, which tells the pituitary to release LH and FSH. LH drives the testes to make testosterone, and FSH supports sperm production.
- TRT adds testosterone from outside. The brain senses it and turns down LH and FSH, which is why sperm production falls.[1]
- hCG acts like LH directly on the testes.[6] In healthy men whose own LH was suppressed by testosterone, low-dose hCG maintained testosterone levels inside the testes.[7]
- Gonadorelin is a copy of GnRH. Given in pulses by pump, it induced puberty in men whose brains made too little GnRH.[8]
- Kisspeptin-10 acts upstream of GnRH. In small studies it raised LH in healthy men,[10] and it raised LH and testosterone in men with type 2 diabetes and mildly low testosterone.[11]
- Growth hormone peptides (sermorelin, ipamorelin, CJC-1295 and others) work on a separate system. See peptides vs HGH.
Evidence quality
TRT has the strongest data of any option here:
- Testosterone Trials: in 790 men aged 65 and older with low testosterone and symptoms, a year of testosterone gel moderately improved sexual function and slightly improved mood, but did not improve vitality or walking distance in the main physical function trial.[2]
- TRAVERSE: in men aged 45 to 80 with heart disease or high risk, major cardiac events occurred in 7.0% on testosterone and 7.3% on placebo.[3]
Axis peptides have mostly small, short studies measuring hormone levels.[7][10][11] hCG is approved for hypogonadotropic hypogonadism in men, but its use alongside TRT to protect fertility is off-label.[6][7]
Growth hormone peptides with TRT: in a retrospective review, 14 men on testosterone who took GHRP-6, GHRP-2 and sermorelin three times daily saw IGF-1 rise from about 160 to 239 ng/mL. It reported hormone levels, not muscle, fat or safety outcomes.[13]
Side effects and safety
TRT
- Blood pressure: in February 2025, FDA required a blood pressure warning on all testosterone products after monitoring studies showed increases.[4]
- Heart rhythm, kidneys and clots: in TRAVERSE, atrial fibrillation, acute kidney injury and pulmonary embolism were more common on testosterone.[3]
- Red blood cells and fertility: the Endocrine Society advises monitoring hematocrit and recommends against TRT in men planning fertility soon.[1]
Peptides
- hCG: its label lists headache, irritability, fluid retention and breast enlargement among possible effects.[6]
- Kisspeptin-10: FDA lists it among compounding substances that may present significant safety risks.[12]
- Growth hormone peptides: a 2026 review reported blood sugar problems, fluid retention and raised prolactin or cortisol across the class.[14]
Doses and monitoring
TRT doses are set and adjusted by a clinician. In TRAVERSE, men used 1.62% testosterone gel daily, with the dose adjusted to keep testosterone between 350 and 750 ng/dL.[3] In the Testosterone Trials, gel raised levels to the mid-normal range for men aged 19 to 40.[2] The Endocrine Society recommends monitoring testosterone levels and hematocrit during treatment, along with prostate monitoring in appropriate men.[1]
hCG doses for hypogonadotropic hypogonadism follow its label.[6] Its use with TRT to protect fertility is off-label and based on small studies, such as one in healthy men given low doses while their own LH was suppressed.[7] Gonadorelin’s key male study used a pulsatile pump, not the occasional shots used today.[8] Kisspeptin-10 doses come only from research studies.[10]
Legal status and 2025-2026 changes
- TRT: a prescription drug and Schedule III controlled substance.[15] In February 2025, FDA removed the cardiovascular boxed warning, added TRAVERSE results and kept the limitation on age-related low testosterone.[4] In June 2026, FDA requested label updates that would remove that limitation and revise warnings on prostate cancer and enlarged prostate. These are requested changes, not final labels.[5]
- hCG: approved prescription drug.[6]
- Gonadorelin: the approved U.S. product, Factrel, is discontinued.[9]
- Kisspeptin-10: not approved and on FDA’s safety-risk list.[12]
- Sport: WADA bans testosterone, hCG (in men) and growth hormone peptides.[16]
Generic and brand testosterone products both exist, and insurance coverage varies by plan. This is general information, not legal advice.
Who each may suit: questions for your clinician
- Has low testosterone been confirmed? The guideline calls for symptoms plus consistently low morning blood tests.[1]
- Do you want children in the next year or two? TRT suppresses sperm production; ask whether hCG or another approach fits.[1][7]
- Is the cause in the testes or the pituitary? Signal-based peptides need working testes.[6]
- Do you have heart, kidney or clotting problems? Ask how TRAVERSE findings apply to you.[3]
The verdict
For diagnosed hypogonadism, TRT is the best-studied treatment, with reassuring heart-safety data and known risks such as higher blood pressure and suppressed fertility.[3][4] hCG is a proven option when the problem is in the pituitary or brain.[6] Other peptides have small hormone studies but no outcome trials, and growth hormone peptides do not raise testosterone. Related: peptides vs SARMs, peptides vs prohormones and IGF-1 LR3 vs MGF.
